Literature DB >> 19732811

Noninvasive delivery of siRNA into the epidermis by iontophoresis using an atopic dermatitis-like model rat.

K Kigasawa1, K Kajimoto, S Hama, A Saito, K Kanamura, K Kogure.   

Abstract

Topical application of siRNA to the skin should be an effective treatment for serious skin disorders, such as atopic dermatitis. However, it is difficult to introduce hydrophilic macromolecules, including siRNA, into the skin by conventional methods. For efficient delivery of siRNA, we examined an iontophoretic technique, since it is suitable for the delivery of charged molecules. Naked siRNA effectively accumulated in the epidermis (and not in the dermis) after iontophoretic delivery. In contrast, siRNA did not penetrate tape-stripped skin by passive diffusion. In a rat model of atopic dermatitis, skin was sensitized with ovalbumin to stimulate IL-10 mRNA expression as observed in skin lesions. Iontophoretic delivery of anti-IL-10 siRNA significantly reduced (73%) the level of IL-10 mRNA. In conclusion, we successfully delivered naked siRNA into the epidermis and concomitantly suppressed the expression of an endogenous immuno-regulatory cytokine.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19732811     DOI: 10.1016/j.ijpharm.2009.08.036

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  17 in total

Review 1.  Skin permeabilization for transdermal drug delivery: recent advances and future prospects.

Authors:  Carl M Schoellhammer; Daniel Blankschtein; Robert Langer
Journal:  Expert Opin Drug Deliv       Date:  2014-01-07       Impact factor: 6.648

2.  Electric stimulus opens intercellular spaces in skin.

Authors:  Susumu Hama; Yuki Kimura; Aya Mikami; Kanako Shiota; Mao Toyoda; Atsushi Tamura; Yukio Nagasaki; Kiyoshi Kanamura; Kazuaki Kajimoto; Kentaro Kogure
Journal:  J Biol Chem       Date:  2013-12-06       Impact factor: 5.157

Review 3.  Delivery of intracellular-acting biologics in pro-apoptotic therapies.

Authors:  Hongmei Li; Chris E Nelson; Brian C Evans; Craig L Duvall
Journal:  Curr Pharm Des       Date:  2011       Impact factor: 3.116

4.  Delivery of siRNA and other macromolecules into skin and cells using a peptide enhancer.

Authors:  Tracy Hsu; Samir Mitragotri
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-08       Impact factor: 11.205

Review 5.  Novel drug delivery strategies and gene therapy regimen as a promising perspective for management of psoriasis.

Authors:  Sujata Pralhad Sawarkar; Vijay Yadav
Journal:  Indian J Dermatol Venereol Leprol       Date:  2021 May-Jun       Impact factor: 2.545

Review 6.  Prospects for Therapeutic Targeting of MicroRNAs in Human Immunological Diseases.

Authors:  Marisa E Luck; Stefan A Muljo; Colm B Collins
Journal:  J Immunol       Date:  2015-06-01       Impact factor: 5.422

Review 7.  Nucleic acid delivery into skin for the treatment of skin disease: Proofs-of-concept, potential impact, and remaining challenges.

Authors:  Michael Zakrewsky; Sunny Kumar; Samir Mitragotri
Journal:  J Control Release       Date:  2015-09-15       Impact factor: 9.776

8.  Therapeutic RNAi robed with ionic liquid moieties as a simple, scalable prodrug platform for treating skin disease.

Authors:  Michael Zakrewsky; Samir Mitragotri
Journal:  J Control Release       Date:  2016-09-06       Impact factor: 9.776

9.  Visualization of plasmid delivery to keratinocytes in mouse and human epidermis.

Authors:  Emilio González-González; Yeu-Chun Kim; Tycho J Speaker; Robyn P Hickerson; Ryan Spitler; James C Birchall; Maria Fernanda Lara; Rong-Hua Hu; Yanhua Liang; Nancy Kirkiles-Smith; Mark R Prausnitz; Leonard M Milstone; Christopher H Contag; Roger L Kaspar
Journal:  Sci Rep       Date:  2011-11-15       Impact factor: 4.379

10.  Topical Anti-Nuclear Factor-Kappa B Small Interfering RNA with Functional Peptides Containing Sericin-Based Hydrogel for Atopic Dermatitis.

Authors:  Takanori Kanazawa; Yuki Shizawa; Mayu Takeuchi; Kuniko Tamano; Hisako Ibaraki; Yasuo Seta; Yuki Takashima; Hiroaki Okada
Journal:  Pharmaceutics       Date:  2015-09-07       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.